GEM (Boston Scientific)
Prostate cancer is the most frequent cancer in European men, and 30 million are confronted with the diagnosis in their lifetimes. In the U.K. a man finds out he has the disease every 11 minutes.
This November, we're putting down the razor and picking up the cause by participating in the Grow & Give campaign with ZERO - The End of Prostate Cancer. Together, we can end the suffering of prostate cancer.
We're raising awareness and funds to protect and expand prostate cancer research, an effort that has already resulted in three new drugs for advanced prostate cancer, as well as worldwide adaptation of a new test for exposing the most deadly forms of the disease.
We're growing education and awareness to save lives. Studies show that discovering prostate cancer early can cut mortality rates by one-fifth, but questionnaires show that less than half of all men are even aware of the disease.
Boston Scientific is proud to support ZERO and the work they're doing to end the disease, raise awareness that saves lives, and offer patient programs that go directly to helping men and their families.
 "Prostate Cancer Statistics," Cancer Research UK, accessed October 7, 2019, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Zero.
 Deschamps, A. "It's time for a new Europe-wide strategy on prostate cancer," Health Europea Quarterly 08 (February 2019): 134.